Full Press Release Details
ALX Oncology to Collaborate with Lilly to Evaluate ALX148 Plus CYRAMZA (Ramucirumab), Trastuzumab, and Paclitaxel in Patients with Gastric or Gastroesophageal Junction Cancer.
ALXO
ALX Oncology to Collaborate with Lilly to Evaluate ALX148 Plus CYRAMZA (Ramucirumab), Trastuzumab, and Paclitaxel in Patients with Gastric or Gastroesophageal Junction Cancer
Key Takeaway: ALX Oncology to Collaborate with Lilly to Evaluate ALX148 Plus CYRAMZA (Ramucirumab), Trastuzumab, and Paclitaxel in Patients with Gastric or Gastroesophageal Junction Cancer
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+102%
120-day peak, hindsight
Typical move
7.9%
average across 6 past catalysts
Cash runway
~25 mo
Minimal dilution risk
Lead asset
ALX2004
Phase 1 · NSCLC (Advanced Non-small Cell Lung Cancer)